This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Arrayit Corporation Announces Life Sciences Instrument Sale To Top Research Center In Ontario

Arrayit Corporation (OTCBB: ARYC), a life sciences and molecular diagnostics leader, announces today that the company has sold a $166,000 NanoPrint™ LM60PRO Enterprise Level Protein Edition Microarray Printer and accessories to a top research center in Ontario, Canada. The Canadian researchers, featured widely in the national and international media, will utilize Arrayit’s patented technology to manufacture protein microarrays for exciting interdisciplinary research applications. Arrayit protein microarrays are powerful devices that contain miniaturized collections of intact proteins, the molecules that comprise the building blocks of all living organisms including humans, plants and animals. Protein microarrays empower researchers with the tools needed to study the structure and function of proteins, which are keys to understanding diverse fundamental research topics including the mode of action of pharmaceutical compounds, human disease progression, synthetic and stem cell biology, ecology and population genetics.

Arrayit has been selling its patented microarray technology since 1997 to empower the proliferation of microarray technology worldwide. Installed in more than 4,000 laboratories, Arrayit’s foundational technology has been used to manufacture an estimated 100,000,000 microarray devices in university laboratories, biotechnology, diagnostics and pharmaceutical companies, and government centers. The company uses revenue from its life sciences research sales for continued innovation, diagnostics research and development, and to keep pace with market leaders Agilent, Illumina and Affymetrix. The company’s research accounts also provide a continuous commercialization pipeline through structured licensing and royalty agreements with laboratories wishing to commercialize their important discoveries.

Arrayit recently completed a $1M equity capital raise and announced the opening of its new and expanded Sunnyvale headquarters on January 1, 2014, which will feature CLIA and ISO laboratories certified with the assistance of DOCRO, the clinical research organization leader from Oxford, Connecticut. DOCRO is also assisting the company in 510(k) submissions to the United States Food and Drug Administration for OvaDx® and PDx™, the company’s pre-symptomatic diagnostic tests for ovarian cancer and Parkinson’s Disease. Arrayit is adding key members to its management and support teams to facilitate growth through organic revenue increases, targeted M&A and the continued infusion of equity capital.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,097.44 -105.93 -0.58%
S&P 500 2,098.48 -9.30 -0.44%
NASDAQ 4,967.7530 -12.1480 -0.24%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs